SAfety of Fondaparinux in transoesophageal echocardiography-guided Electric cardioversion of Atrial Fibrillation (SAFE-AF) study: A pilot study

Archives of Cardiovascular Diseases

Volumn 108, Issue 2, 2015, Pages 122-131

  Cohen, Ariel ^a   Stellbrink, Christoph ^b   Le Heuzey, Jean Yves ^c   Faber, Thomas ^d   Aliot, Etienne ^e   Banik, Norbert ^f   Kropff, Stefan ^g   Omran, Heyder ^h  

^a HÔPITAL SAINT ANTOINE   (France)

^b University Hospital of Bielefeld   (Germany)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d UNIVERSITY OF FREIBURG   (Germany)

^e Institute of Heart and Vessels Louis Mathieu   (France)

^f Winicker Norimed GmbH   (Germany)

^g GLAXOSMITHKLINE   (Germany)

^h ST MARIEN HOSPITAL   (Germany)

Author keywords

Anticoagulant; Atrial fibrillation; Cardioversion; Thrombosis

Indexed keywords

ANTIVITAMIN K; FONDAPARINUX; HEPARIN; ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 10; POLYSACCHARIDE;

ABDOMINAL WALL DEFECT; AGED; ARTICLE; BRAIN HEMORRHAGE; CARDIOVERSION; CAUSE OF DEATH; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; GASTROINTESTINAL HEMORRHAGE; HEART ATRIUM FIBRILLATION; HEART ATRIUM THROMBOSIS; HEMATOMA; HEMORRHAGIC SHOCK; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; RECTUM HEMORRHAGE; RETROPERITONEAL HEMORRHAGE; THROMBOEMBOLISM; TRANSESOPHAGEAL ECHOCARDIOGRAPHY; TREATMENT DURATION; TREATMENT OUTCOME; ANTAGONISTS AND INHIBITORS; ATRIAL FIBRILLATION; CLINICAL TRIAL; COMPUTER ASSISTED SURGERY; MIDDLE AGED; PILOT STUDY;

AGED; ANTICOAGULANTS; ATRIAL FIBRILLATION; ECHOCARDIOGRAPHY, TRANSESOPHAGEAL; ELECTRIC COUNTERSHOCK; FACTOR X; FEMALE; HUMANS; MALE; MIDDLE AGED; PILOT PROJECTS; POLYSACCHARIDES; SURGERY, COMPUTER-ASSISTED; THROMBOEMBOLISM;

EID: 84923688597     PISSN: 18752136     EISSN: 18752128     Source Type: Journal    
DOI: 10.1016/j.acvd.2014.09.009     Document Type: Article

References (20)

1. Krahn AD, Manfreda J, Tate RB, Mathewson FA, Cuddy TE. The natural history of atrial fibrillation: incidence, risk factors, and prognosis in the Manitoba Follow-Up Study. Am J Med 1995;98:476-84.
2. Bjerkelund CJ, Orning OM. The efficacy of anticoagulant therapy in preventing embolism related to D.C. electrical conversion of atrial fibrillation. Am J Cardiol 1969;23:208-16.
3. Arnold AZ, Mick MJ, Mazurek RP, Loop FD, Trohman RG. Role of prophylactic anticoagulation for direct current cardioversion in patients with atrial fibrillation or atrial flutter. J Am Coll Cardiol 1992;19:851-5.
4. Silverman DI, Manning WJ. Roleof echocardiography in patients undergoing elective cardioversion of atrial fibrillation. Circulation 1998;98:479-86.
5. Hwang JJ, Chen JJ, Lin SC, et al. Diagnostic accuracy of transesophageal echocardiography for detecting left atrial thrombi in patients with rheumatic heart disease having undergone mitral valve operations. Am J Cardiol 1993;72:677-81.
6. Klein AL, Jasper SE, Katz WE, et al. The use of enoxa-parin compared with unfractionated heparin for short-term antithrombotic therapy in atrial fibrillation patients undergoing transoesophageal echocardiography-guided cardioversion: assessment of Cardioversion Using Transoesophageal Echocardiography (ACUTE) II randomized multicentre study. Eur Heart J 2006;27:2858-65.
7. Stellbrink C, Nixdorff U, Hofmann T et al. Safety and efficacy of enoxaparin compared with unfractionated heparin and oral anticoagulants for prevention of thromboembolic complications in cardioversion of nonvalvular atrial fibrillation: the Anticoagulation in Cardioversion using Enoxaparin (ACE) trial. Circulation 2004;109:997-1003.
8. Camm AJ, Lip GY, De Caterina R, et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J 2012;33:2719-47.
9. Weinberg DM, Mancini J. Anticoagulation for cardioversion of atrial fibrillation. Am J Cardiol 1989;63:745-6.
10. European Heart Rhythm Association, European Association for Cardio-Thoracic Surgery, Camm AJ, et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Europace 2010;12:1360-420.
11. Fuster V, Ryden LE, Cannom DS, et al. 2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 Guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in partnership with the European Society of Cardiology and in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. J Am Coll Cardiol 2011;57:e101-98.
12. Task Force for Diagnosis, Treatment of Non-ST-Segment Elevation Acute Coronary Syndromes of European Society of Cardiology, Bassand JP, Hamm CW, et al. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. Eur Heart J 2007;28:1598-660.
13. Geerts WH, Bergqvist D, Pineo GF, et al. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008;133:381S-453S.
14. Kearon C, Kahn SR, Agnelli G, et al. Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008;133:454S-545S.
15. Warkentin TE, Davidson BL, Buller HR, etal. Prevalence and risk of preexisting heparin-induced thrombocytopenia antibodies in patients with acute VTE. Chest 2011;140:366-73.
16. Mehran R, Rao SV, Bhatt DL, et al. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation 2011;123:2736-47.
17. Rao AK, Pratt C, Berke A, et al. Thrombolysis in Myocardial Infarction (TIMI) Trial-phase I: hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase. J Am Coll Cardiol 1988;11: 1-11.
18. Klein AL, Grimm RA, Murray RD, et al. Use of transesophageal echocardiography to guide cardioversion in patients with atrial fibrillation. N Engl J Med 2001;344:1411-20.
19. Seidl K, Rameken M, Drogemuller A, et al. Embolic events in patients with atrial fibrillation and effective anticoagulation: value of transesophageal echocardiography to guide direct-current cardioversion. Final results of the Lud-wigshafen Observational Cardioversion Study. J Am Coll Cardiol 2002;39:1436-42.
20. Tebbe U, Oeckinghaus R, Appel KF, et al. AFFECT: a prospective, open-label, multicenter trial to evaluate the feasibility and safety of a short-term treatment with subcutaneous certoparin in patients with persistent non-valvular atrial fibrillation. Clin Res Cardiol 2008;97:389-96.